SCHEMBL2107802

SCHEMBL2107802

Cc1ccc(C(=N)N)c(C)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 4/20 0.48
PRSS2 P07478 2/20 0.48
PRSS3 P35030 2/20 0.48
F2 P00734 4/20 0.45
PLAU P00749 4/20 0.45
F10 P00742 3/20 0.45
PLG P00747 3/20 0.45
PLAT P00750 2/20 0.45
TDP1 Q9NUW8 2/20 0.44
TP53 P04637 1/20 0.44
C1S P09871 1/20 0.43
FURIN P09958 1/20 0.42
NFE2L2 Q16236 1/20 0.40
ALDH1A1 P00352 2/20 0.39
KMT2A Q03164 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2A6 P11509 1/20 0.39
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6478711 0.83 TDP1 (0.50) PRSS1PRSS2PRSS3TDP1TP53
SCHEMBL123847 0.83 CYP2D6 (0.49) PRSS1PRSS2PRSS3F2PLAU
SCHEMBL5260076 0.80 F2 (0.55) PRSS1PRSS2PRSS3F2PLAU
SCHEMBL28210375 0.80 F12 (0.48) PRSS1PRSS2PRSS3F2PLAU
SCHEMBL8212165 0.80 ALDH1A1 (0.50) PRSS1PRSS2PRSS3F2PLAU
SCHEMBL30755246 0.80 F2 (0.55) PRSS1PRSS2PRSS3F2PLAU
SCHEMBL27758947 0.80 ALDH1A1 (0.50) PRSS1PRSS2PRSS3F2PLAU
SCHEMBL24015013 0.79 TRPA1 (0.47) PRSS1PRSS2PRSS3F2PLAU
SCHEMBL17085840 0.79 TDP1 (0.46) TDP1TP53NFE2L2ALDH1A1KMT2A
SCHEMBL8234925 0.78 F2 (0.49) PRSS1PRSS2PRSS3F2PLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250295611-A1 METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS TESSELLATE THERAPEUTICS INC (US) 2025-09-25 US claimed
US-20240390301-A1 COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS GILGAMESH PHARMACEUTICALS, INC. (US) 2024-11-28 US claimed
WO-2023212244-A1 METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS TESSELLATE THERAPEUTICS, INC. (US) 2023-11-02 WO claimed
US-11794009-B2 Devices, systems and methods for treating urological and gastrointestinal disorders by electrical stimulation of the foot University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2023-10-24 US claimed
WO-2023028086-A1 COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS GILGAMESH PHARMACEUTICALS, INC. (US) 2023-03-02 WO claimed
US-20220146492-A1 CELL MEMBRANE PERMEABILITY RESTORING THERAPY SHINE IAN BASIL (US) 2022-05-12 US claimed
EP-3953000-A1 CELL MEMBRANE PERMEABILITY RESTORING THERAPY Shine, Ian Basil (US) 2022-02-16 EP claimed
US-20210370059-A1 Devices, Systems and Methods for Treating Urological and Gastrointestinal Disorders by Electrical Stimulation of the Foot UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2021-12-02 US claimed
WO-2020210643-A1 CELL MEMBRANE PERMEABILITY RESTORING THERAPY SHINE IAN BASIL (US) 2020-10-15 WO claimed
US-20170361091-A1 Devices, Systems and Methods for Treating Urological and Gastrointestinal Disorders by Electrical Stimulation of the Foot UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2017-12-21 US claimed
US-20120282255-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALCOHOLISM AND ALCOHOL DEPENDENCE SUMMIT BIOSCIENCES, INC. 2012-11-08 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
US-7241797-B2 Method of increasing milk production UNIVERSITY OF CINCINNATI (US) 2007-07-10 US claimed
CN-1320354-C Method for analysizing amino acid TIANJIN PHARMACEUTICAL INST CO (CN) 2007-06-06 CN claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
CN-1749748-A Method for analysizing amino acid TIANJIN PHARMACEUTICAL INST CO (CN) 2006-03-22 CN claimed
US-20030139420-A1 Method of increasing milk production NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-07-24 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240390301-A1 COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS HTR2A, HTR2C, HTR5A PRSS1 3657/4885PRSS2 3545/4885PRSS3 4000/4885
US-20250295611-A1 METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS HTR2A, HTR5A, HTR6 PRSS1 2114/4885PRSS2 1696/4885PRSS3 2098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.